Table 2. Reported Neurologic Manifestations of SARS-CoV-2 Infection.^*.

Manifestation	Percentage of Study Patients
Any neurologic manifestation	36.4% (Mao et al.) 57.4% (Romero-Sánchez et al.)
Decreased taste	5.6% (Mao et al.) 28.8% (Giacomelli et al.) 88% (Lechien et al.)
Decreased smell	5.1% (Mao et al.) 23.7% (Giacomelli et al.) 85.6% (Lechien et al.)
Muscle injury or myalgias	10.7% (Mao et al.) 17.2% (Romero-Sánchez et al.) 23.8% (Goyal et al.) 34.8% (Wang et al.) 44% (Huang et al.)
Dizziness	6.1% (Romero-Sánchez et al.) 16.8% (Mao et al.)
Headache	13.1% (Mao et al.) 14.1% (Romero-Sánchez et al.)
Neuropsychiatric disorder (delirium, agitation, or dysexecutive syndrome) or impaired consciousness	7.5% (Mao et al.) 69% (Helms et al.)
Stroke	2.8% (Mao et al.) Present in case series (Oxley et al.)
Nerve pain	2.3% (Mao et al.)
Vision disturbance or optic neuritis	<1% (Romero-Sánchez et al.) 1.4% (Mao et al.)
Ataxia or movement disorder	<1% (Mao et al. and Romero-Sánchez et al.)
Seizure	<1% (Mao et al., Lu et al., and Romero-Sánchez et al.)
Guillain–Barré syndrome, Miller Fisher syndrome, or ophthalmoparesis	Present in case report (Zhao et al.) and case series (Toscano et al., Gutiérrez-Ortiz et al., and Dinkin et al.)
Acute necrotizing encephalopathy	Present in case report (Poyiadji et al.)
Meningoencephalitis	Present in case report (Moriguchi et al.)
Myelitis	Present in case report (Zhao et al.) Present in case report (Sotoca et al.)

^*The study by Mao et al.⁵ (conducted in China) included 214 patients, Romero-Sánchez et al.³⁴ 841 patients, Giacomelli et al.³⁵ (an inpatient study) 59 patients, Lechien et al.³⁶ (an outpatient study) 417 patients, Goyal et al.³⁷ 393 patients, Wang et al.³⁸ 138 patients, Huang et al.³⁹ 41 patients, Helms et al.⁶ 58 patients, Oxley et al.⁴⁰ 5 patients, Lu et al.⁷ 304 patients, Zhao et al.⁴¹ 1 patient, Toscano et al.⁴² 5 patients, Gutiérrez-Ortiz et al.⁴³ 2 patients, Dinkin et al.⁴⁴ 2 patients, Poyiadji et al.⁴⁵ 1 patient, Moriguchi et al.⁴⁶ 1 patient, and Sotoca et al.⁴⁷ 1 patient.